Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 9Recurrence 5Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Sarcoma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Vascular Neoplasms 1Triple Negative Breast Neoplasms 1Solitary Fibrous Tumors 1Solid Tumor Malignancy 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Adipose Tissue 1Neoplasm Metastasis 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma, Myxoid 1Liposarcoma 1

Interventions

selinexor 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrent Squamous Cell Lung Carcinoma × selinexor × Clear all
NCT02536495 2015-10-30

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2 Withdrawn

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡